REGN Stock Analysis: Regeneron Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 65.015m USD | 12M Return: 17.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 640M
EPS Trend: 58.1%
Qual. Beats: 0
Rev. Trend: 96.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Regeneron Pharmaceuticals is a U.S.-based biotechnology company that discovers, develops, manufactures, and commercializes medicines across a broad range of therapeutic areas, including eye diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, neurological and infectious diseases, rare diseases, and oncology. Its commercial portfolio includes EYLEA (for retinal conditions including wet age-related macular degeneration), Dupixent (atopic dermatitis and asthma), Libtayo (cutaneous squamous cell carcinoma), Praluent (high cholesterol), and Kevzara (rheumatoid arthritis).
The business model relies heavily on proprietary R&D platforms and a network of strategic collaborations with major partners, including Bayer (EYLEA), Alnylam (RNAi therapeutics), Intellia (CRISPR/Cas9 gene editing), Hansoh (dual GLP-1/GIP receptor programs), Tessera (gene editing for Alpha-1 antitrypsin deficiency), Telix (radiopharmaceuticals), and CytomX (conditionally-activated bispecific cancer therapies). The company was founded in 1988 and is headquartered in Tarrytown, New York.
- EYLEA sales face Vabysmo competition pressure
- Dupixent label expansions accelerate immunology revenue growth
- GLP-1 deal with Hansoh expands obesity pipeline exposure
| Net Income: 4.42b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 2.12 > 1.0 |
| NWC/Revenue: 87.81% < 20% (prev 99.43%; Δ -11.61% < -1%) |
| CFO/TA 0.12 > 3% & CFO 5.01b > Net Income 4.42b |
| Net Debt (-5.33b) to EBITDA (5.74b): -0.93 < 3 |
| Current Ratio: 3.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (107.7m) vs 12m ago -3.15% < -2% |
| Gross Margin: 84.55% > 18% (prev 85.79%; Δ -1.25% > 0.5%) |
| Asset Turnover: 38.05% > 50% (prev 37.52%; Δ 0.54% > 0%) |
| Interest Coverage Ratio: 108.4 > 6 (EBIT TTM 5.20b / Interest Expense TTM 48.0m) |
| A: 0.32 (Total Current Assets 18.2b - Total Current Liabilities 5.11b) / Total Assets 40.9b |
| B: 0.89 (Retained Earnings 36.4b / Total Assets 40.9b) |
| C: 0.13 (EBIT TTM 5.20b / Avg Total Assets 39.2b) |
| D: 3.33 (Book Value of Equity 31.4b / Total Liabilities 9.45b) |
| Altman-Z'' = 9.39 = AAA |
| DSRI: 0.97 (Receivables 5.73b/5.56b, Revenue 14.9b/14.1b) |
| GMI: 1.01 (GM 85.79% / 84.55%) |
| AQI: 1.05 (AQ_t 0.43 / AQ_t-1 0.41) |
| SGI: 1.06 (Revenue 14.9b / 14.1b) |
| TATA: -0.01 (NI 4.42b - CFO 5.01b) / TA 40.9b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of July 02, 2026, the stock is trading at USD 624.72 with a total of 987,285 shares traded. Over the past week, the price has changed by +0.21%, over one month by +4.01%, over three months by -19.50% and over the past year by +17.43%.
Current recommended Stop Loss: 585.90 (which is 6.2% or 2.4 ATR below the current price).
Regeneron Pharmaceuticals has received a consensus analysts rating of 4.28. Therefore, it is recommended to buy REGN.
- StrongBuy: 14
- Buy: 5
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 833.3 | 33.4% |
P/E Trailing = 15.1512
P/E Forward = 13.8122
P/S = 4.3577
P/B = 2.069
P/EG = 1.0713
Revenue TTM = 14.9b USD
EBIT TTM = 5.20b USD
EBITDA TTM = 5.74b USD
Long Term Debt = 1.99b USD (from longTermDebt, last quarter)
Short Term Debt = 720.0m USD (from shortTermDebt, last quarter)
Debt = 3.43b USD (from shortLongTermDebtTotal, last quarter) + Leases 720.0m
Net Debt = -5.33b USD (calculated: Debt 3.43b - CCE 8.75b)
Enterprise Value = 59.7b USD (65.0b + Debt 3.43b - CCE 8.75b)
Interest Coverage Ratio = 108.4 (Ebit TTM 5.20b / Interest Expense TTM 48.0m)
EV/FCF = 14.36x (Enterprise Value 59.7b / FCF TTM 4.16b)
FCF Yield = 6.96% (FCF TTM 4.16b / Enterprise Value 59.7b)
FCF Margin = 27.85% (FCF TTM 4.16b / Revenue TTM 14.9b)
Net Margin = 29.65% (Net Income TTM 4.42b / Revenue TTM 14.9b)
Gross Margin = 84.55% ((Revenue TTM 14.9b - Cost of Revenue TTM 2.31b) / Revenue TTM)
Gross Margin QoQ = 81.43% (prev 84.95%)
Tobins Q-Ratio = 1.46 (Enterprise Value 59.7b / Total Assets 40.9b)
Interest Expense / Debt = 1.40% (Interest Expense 48.0m / Debt 3.43b)
Taxrate = 14.22% (733.5m / 5.16b)
NOPAT = 4.46b (EBIT 5.20b * (1 - 14.22%))
Current Ratio = 3.57 (Total Current Assets 18.2b / Total Current Liabilities 5.11b)
Debt / Equity = 0.11 (Debt 3.43b / totalStockholderEquity, last quarter 31.4b)
Debt / EBITDA = -0.93 (Net Debt -5.33b / EBITDA 5.74b)
Debt / FCF = -1.28 (Net Debt -5.33b / FCF TTM 4.16b)
Total Stockholder Equity = 30.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.28% (Net Income 4.42b / Total Assets 40.9b)
RoE = 14.32% (Net Income TTM 4.42b / Total Stockholder Equity 30.9b)
RoCE = 15.83% (EBIT 5.20b / Capital Employed (Equity 30.9b + L.T.Debt 1.99b))
RoIC = 12.49% (NOPAT 4.46b / Invested Capital 35.7b)
WACC = 7.61% (E(65.0b)/V(68.4b) * Re(7.95%) + D(3.43b)/V(68.4b) * Rd(1.40%) * (1-Tc(0.14)))
Discount Rate = 7.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -58.43 | Cagr: -2.42%
[DCF] Terminal Value 77.97% ; FCFF base≈3.70b ; Y1≈4.24b ; Y5≈6.24b
[DCF] Fair Price = 963.8 (EV 94.0b - Net Debt -5.33b = Equity 99.3b / Shares 103.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 58.07 | EPS CAGR: 1.16% | SUE: 0.36 | # QB: 0
Revenue Correlation: 96.57 | Revenue CAGR: 5.39% | SUE: 0.68 | # QB: 0
EPS current Quarter (2026-09-30): EPS=13.08 | Chg30d=+0.59% | Revisions=+30% | Analysts=23
EPS current Year (2026-12-31): EPS=46.25 | Chg30d=-0.27% | Revisions=+31% | GrowthEPS=+4.4% | GrowthRev=+10.7%
EPS next Year (2027-12-31): EPS=48.10 | Chg30d=+0.07% | Revisions=+8% | GrowthEPS=+24.5% | GrowthRev=+10.5%
[Analyst] Revisions Ratio: +31%